Tumor progression and the different faces of the PERK kinase
- PMID: 26028033
- PMCID: PMC4666839
- DOI: 10.1038/onc.2015.178
Tumor progression and the different faces of the PERK kinase
Abstract
The serine/threonine endoplasmic reticulum (ER) kinase, protein kinase R (PKR)-like ER kinase (PERK), is a pro-adaptive protein kinase whose activity is regulated indirectly by protein misfolding within the ER. As the oxidative folding environment in the ER is sensitive to a variety of cellular stresses, many of which occur during neoplastic transformation and in the tumor microenvironment, there has been considerable interest in defining whether PERK positively contributes to tumor progression and whether it represents a significant therapeutic target. Herein, we review the current knowledge of PERK-dependent signaling pathways, the contribution of downstream substrates including recently characterized new PERK substrates transcription factors Forkhead box O protein and diacyglycerol a lipid signaling second messenger, and efforts to develop small molecule PERK inhibitors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4666839/bin/nihms681586f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4666839/bin/nihms681586f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4666839/bin/nihms681586f3.gif)
Similar articles
-
Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. doi: 10.1080/13543776.2017.1238072. Epub 2016 Sep 23. Expert Opin Ther Pat. 2017. PMID: 27646439 Review.
-
PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development.J Cell Physiol. 2016 Oct;231(10):2088-96. doi: 10.1002/jcp.25336. Epub 2016 Mar 6. J Cell Physiol. 2016. PMID: 26864318 Free PMC article. Review.
-
Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy.Hepatol Int. 2014 Oct 1;9(1):93-104. doi: 10.1007/s12072-014-9582-0. eCollection 2015 Jan. Hepatol Int. 2014. PMID: 25598862 Free PMC article.
-
TBL2 is a novel PERK-binding protein that modulates stress-signaling and cell survival during endoplasmic reticulum stress.PLoS One. 2014 Nov 13;9(11):e112761. doi: 10.1371/journal.pone.0112761. eCollection 2014. PLoS One. 2014. PMID: 25393282 Free PMC article.
-
PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage.Oncogene. 2010 Jul 8;29(27):3881-95. doi: 10.1038/onc.2010.153. Epub 2010 May 10. Oncogene. 2010. PMID: 20453876 Free PMC article.
Cited by
-
Cucurbitacin B induces apoptosis in colorectal cells through reactive oxygen species generation and endoplasmic reticulum stress pathways.Exp Ther Med. 2023 Sep 1;26(4):484. doi: 10.3892/etm.2023.12183. eCollection 2023 Oct. Exp Ther Med. 2023. PMID: 37753296 Free PMC article.
-
UPR-Induced miR-616 Inhibits Human Breast Cancer Cell Growth and Migration by Targeting c-MYC.Int J Mol Sci. 2023 Aug 22;24(17):13034. doi: 10.3390/ijms241713034. Int J Mol Sci. 2023. PMID: 37685841 Free PMC article.
-
Deubiquitylase OTUD3 Mediates Endoplasmic Reticulum Stress through Regulating Fortilin Stability to Restrain Dopaminergic Neurons Apoptosis.Antioxidants (Basel). 2023 Mar 26;12(4):809. doi: 10.3390/antiox12040809. Antioxidants (Basel). 2023. PMID: 37107185 Free PMC article.
-
How the Unfolded Protein Response Is a Boon for Tumors and a Bane for the Immune System.Immunohorizons. 2023 Apr 1;7(4):256-264. doi: 10.4049/immunohorizons.2200064. Immunohorizons. 2023. PMID: 37067519 Free PMC article. Review.
-
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses.Cancer Cell. 2022 Oct 10;40(10):1145-1160.e9. doi: 10.1016/j.ccell.2022.08.016. Epub 2022 Sep 22. Cancer Cell. 2022. PMID: 36150390 Free PMC article.
References
-
- Schroder M. The unfolded protein response. Mol Biotechnol. 2006;34:279–290. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials